Cooling and Antisolvent Crystallization Patents: Top Companies & Trends 2026
- Filings peaked in 2017 at 119 and fell 73% from 2021 (80) to 2024 (22), the last year the dataset treats as complete — a genuine pullback in new filing, not a publication-lag artefact.
- The ranked leader holds 130 records while the field's top 10 combined account for 43.3% of all 1,017 records, leaving a long tail of single- and few-filing entrants below that line.
- C07D heterocyclic chemistry touches 41.4% of records and B01D separation processes only 15.6%, showing claims cluster on the compound side far more than on the crystallizer hardware or separation step.
Filing growth compares 2021 (80 records) with 2024 (22) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,017 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent families that combine cooling or antisolvent crystallization with explicit process controls — supersaturation control, seeding strategy, cooling profile, addition rate, nucleation induction or crystal size distribution. That combination narrows the field to documents where crystallization is treated as an engineered, controlled unit operation rather than a passive purification step, which is why pharmaceutical assignees dominate the ranking rather than bulk commodity chemical producers.
Records span 2015 through the 2026 data cut-off, drawing on receiving offices led by the United States, the European Patent Office and the WIPO PCT route, with meaningful volume also filed into Canada, Australia and India.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 1,017-record set: how filing volume has moved year over year, and which IPC subclasses carry the claims.
A sharp rise-and-fall filing curve
Filings climbed to a peak of 119 in 2017, then declined through the following years; the 2021-to-2024 window alone shows an -73% drop (80 to 22), the last span the dataset treats as complete since publication typically lags filing by around 18 months.
Compound chemistry outweighs hardware claims
C07D (heterocyclic compounds, 41.4% of records) and A61K (medicinal preparations, 36.8%) lead the composition, with A61P (therapeutic activity, 27.7%) and C07C (acyclic/carbocyclic compounds, 21.8%) close behind. B01D (separation processes, 15.6%), C07H (sugars and nucleic acids, 8.5%), C07F (organo-metallic compounds, 8.1%) and C07B (general organic methods, 5.7%) trail well behind — the crystallization control claims in this corpus are filed mostly to protect a molecule or formulation, not the separation apparatus itself.
Shares are the percentage of the 1,017 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cooling and Antisolvent Crystallization Control with Eureka
This page is one run against one query. Ask Eureka your own question about cooling and antisolvent crystallization control and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
US20060096525A1 — Solid hollow fiber cooling crystallization systems and methods
A solid hollow fiber cooling crystallizer and method for crystallizing aqueous and organic solutions are provided. The crystallizer uses a bundle of non-porous hollow fibers mounted within a shell, where a feed solution flows through the fiber lumen and a cooling solution flows through the shell side to form nuclei and subsequently crystals below the feed's saturation temperature. The device can be combined with a mixing stage to manage crystal growth.Filed by New Jersey Institute of Technology, published 2006-05-11.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20020160109A1 | Microencapsulation of drugs by solvent exchange | 198 |
| 2 | US6013835A | Method and apparatus for preparing purified terephthalic acid | 134 |
| 3 | US5840968A | Method and apparatus for preparing purified terephthalic acid | 130 |
| 4 | US6599627B2 | Microencapsulation of drugs by solvent exchange | 118 |
| 5 | US7572789B2 | Salts of potassium ATP channel openers and uses thereof | 78 |
| 6 | WO2019018406A1 | Methods for the purification of l-glufosinate | 56 |
| 7 | US5980640A | Method for recovering an organic compound from solutions | 54 |
| 8 | US8962829B1 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | 46 |
| 9 | WO2018112382A1 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | 35 |
| 10 | EP2360137A1 | Process for manufacturing succinic acid | 33 |
Citation counts reflect the searched corpus and skew toward older filings; treat them as a signal of influence, not current relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about this field
Three patterns stand out once filing volume, concentration and technology composition are read together.
A field past its filing peak
Volume peaked in 2017 at 119 filings and has fallen steadily since; the 2021-to-2024 window, the last one the dataset treats as complete, shows an -73% decline from 80 to 22 filings. That is a real pullback in new patenting activity around this specific control-parameter combination, not an artefact of publication lag.
Concentrated at the top, long tail below
The leader holds 130 records and the top five combined account for 29.9% of all 1,017 records in scope. The top 10 extend that to 43.3%, meaning more than half the corpus is spread across a long tail of smaller and single-filing entrants.
Molecule claims outnumber process-hardware claims
C07D heterocyclic compounds appear in 41.4% of records versus 15.6% for B01D separation processes, indicating that most applicants are protecting the compound or formulation produced by a controlled crystallization step rather than the crystallizer or filtration hardware itself.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cooling and antisolvent crystallization control, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Essentialis Inc | COWEN NEIL M | 3 |
| Essentialis Inc | YAMOUT KHALED A | 2 |
| Essentialis Inc | SOLENO THERAPEUTICS INC | 2 |
| Essentialis Inc | KASHKIN KENNETH B | 2 |
| BASF SE | Agrimetis LLC | 2 |
| PTC Therapeutics Inc | Emergent BioDefense Operations Lansing LLC | 2 |
| PTC Therapeutics Inc | Bioelectronics Technology Co Ltd | 2 |
| Ariad Pharmaceuticals Inc | Takeda Pharmaceutical Company Limited | 2 |
Only 10 co-assignee pairs appear across the corpus, and none of the tracked leaders show any filings in the latest year — a field where solo filing dominates and near-term momentum has gone quiet across the top names.
Who holds the claims, and where the gaps sit
The ranking spans 100 companies with volume concentrated at the top and a long tail beneath it; recent-year filing activity has slowed across the tracked leaders.
One filer well ahead of the field
The top-ranked assignee holds 130 records, well clear of the fifth-place holder at 35 and the tenth-place holder at 20 — a steep drop-off rather than a gradual one.
A tight cluster just below the leader
Positions five through ten sit in a narrower band, from 35 down to 20 records, before volume thins out into the long tail that makes up the remainder of the ranked 100.
Recent-year filing has gone quiet at the top
None of the tracked leading assignees show filings in the latest year, consistent with the broader post-2021 decline in volume across the field, though the most recent years are still filling in under normal publication lag.
| Assignee | Recent year | YoY |
|---|---|---|
| Janssen Pharmaceutica NV | 0 | — |
| Essentialis Inc | 0 | — |
| BASF SE | 0 | — |
| Xyrofin Oy | 0 | — |
| PTC Therapeutics Inc | 0 | — |
| Signal Pharmaceuticals LLC | 0 | — |
| PTC Therapeutics Inc | 0 | — |
| Ariad Pharmaceuticals Inc | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing or new filing strategy.
Check freedom-to-operate against the top 10
With 43.3% of all 1,017 records held by ten assignees, a clearance search should start there before broadening to the long tail.
Run a freedom-to-operate checkTest claim scope in the under-claimed branches
Separation-process and hardware classes carry far fewer filings than compound classes, suggesting room for narrowly drafted claims in those areas.
Explore white space with EurekaWatch for renewed filing once the lag clears
2025-2026 volume is still filling in under the roughly 18-month publication lag, so the apparent decline should be revisited once those years mature.
Track filing trendsCommon questions on this landscape
The ranking covers 100 companies, with the leading assignee holding 130 records against a fifth-place total of 35 and a tenth-place total of 20. That drop-off shows a genuinely concentrated top rather than an even spread. Together the top 10 account for 43.3% of all 1,017 records in scope, meaning the remaining majority is spread across a long tail of smaller filers, so a full competitive picture requires looking well past the leading names.
Filing peaked in 2017 at 119 and has declined since, with the 2021-to-2024 window — the last period the dataset treats as complete — showing a -73% drop from 80 to 22 filings. That is a real reduction in new patenting activity around this specific control-parameter combination, not simply a data artefact. Because publication typically lags filing by around 18 months, the 2025-2026 figures are still filling in and should not be read as confirming a continued decline.
C07D heterocyclic compounds appear in 41.4% of the 1,017 records and A61K medicinal preparations in 36.8%, making compound and formulation chemistry the dominant claim focus. A61P therapeutic activity and C07C acyclic/carbocyclic compounds follow at 27.7% and 21.8% respectively. B01D separation processes, which cover crystallizer and filtration hardware more directly, appear in only 15.6% of records, indicating that hardware-level claiming is comparatively rare relative to the molecule side.
The separation-process and hardware-adjacent classes, such as B01D, carry noticeably lower filing density than the compound-chemistry classes, which suggests room for claims tied to crystallizer design, in-line crystal size distribution feedback or continuous antisolvent addition control. Co-filing is also unusually rare in this corpus, with only 10 co-assignee pairs recorded, pointing to limited collaborative claiming that a new entrant could exploit through joint development agreements. Any white-space assessment should still be checked against the specific claim language of the leading assignees' portfolios before filing.
US20060096525A1, filed by New Jersey Institute of Technology and published in 2006, covers a solid hollow fiber cooling crystallizer that runs feed solution through non-porous hollow fiber lumens while a cooling solution circulates on the shell side to induce nucleation and crystal growth below the feed's saturation temperature. It is a hardware-and-method claim tied specifically to that hollow-fiber, shell-and-tube style configuration. Designs that achieve cooling crystallization through other means, such as jacketed vessel cooling, external heat exchangers or antisolvent addition without a hollow-fiber membrane, sit outside its literal claim scope, though a full clearance opinion would need to review the specific claim language rather than the abstract alone.
Research Cooling and Antisolvent Crystallization Control in depth with Eureka
Go past this page: query the whole cooling and antisolvent crystallization control corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.